Iclaprim - Motif Bio

Drug Profile

Iclaprim - Motif Bio

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 01 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio
  • Class Antibacterials; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Skin and soft tissue infections
  • Phase II Nosocomial pneumonia
  • Phase I Nosocomial infections
  • Preclinical Methicillin-resistant Staphylococcus aureus infections
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 25 Sep 2018 Iclaprim - Motif Bio is available for licensing in Asia, Europe, Latin America, Canada as of 25 Sep 2018. https://www.motifbio.com/partnering/
  • 25 Sep 2018 Motif Bio announces intention to launch Iclaprim for Skin and soft tissue infections in USA in first half of 2019
  • 25 Sep 2018 Motif Bio plans a phase III trial for Nosocomial pneumonia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top